Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating profit decreased due to changes in the product mix associated with the transfer of part of the Asian business, higher selling and R&D expenses, and the absence of the gain on the transfer of equity interests in affiliates recorded in the same period of the previous year, despite expanded sales of Orgovyx and Gemtesa in the US and the benefit of the weaker yen.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥266,490 million (YoY +17.3%) |
| Operating profit | ¥42,276 million (YoY -56.0%) |
| Ordinary income | ¥39,382 million (YoY -57.6%) |
| Profit attributable to owners of the parent | ¥38,238 million (YoY -61.3%) |
| Net income per share | ¥86.48 |
| Equity ratio | End of the current fiscal period 50.7 / End of previous period 36.4 |
| Total assets | ¥851,053 million |
| Net assets | ¥431,105 million |
| Cash flows from operating activities | ¥16,673 million |
| Cash flows from investing activities | ¥535 million |
| Cash flows from financing activities | ¥17,580 million |
| Cash and cash equivalents at end of period | ¥77,759 million |
| Full-year earnings forecast | Net Sales ¥565,000 million (YoY +24.6%) / Operating profit ¥104,000 million (YoY -3.1%) / Ordinary income Not disclosed / Net income ¥94,000 million (YoY -12.0%) |
| Revision to Earnings Forecast | Net Sales ¥540,000 million → ¥565,000 million（+4.6%） / Core operating profit ¥91,000 million → ¥105,000 million（+15.4%） / Operating profit ¥90,000 million → ¥104,000 million（+15.6%） / Profit for the period attributable to owners of the parent ¥77,000 million → ¥94,000 million（+22.1%） |
| Annual Dividend Forecast | 0 yen → 15 yen |
| Regional sales | United States Net Sales ¥197.8 billion / Year-on-year change ¥40.8 billion increase in revenue / Japan Net Sales ¥44.6 billion / Year-on-year change ¥1.8 billion increase in revenue / Other Net Sales ¥24.1 billion / Year-on-year change ¥3.2 billion decrease in revenue |
| Depreciation and amortization | ¥9,777 million |
| Impairment loss | ¥16 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Material subsequent events | None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors, securities analysts and media representatives |
| Issued Shares at Period-End | 449,204,554 shares |
| Treasury Shares at Period-End | 611,469 shares |
| Factors Behind Changes in Business Performance | Operating profit decreased due to changes in the product mix associated with the transfer of part of the Asian business, higher selling and R&D expenses, and the absence of the gain on the transfer of equity interests in affiliates recorded in the same period of the previous year, despite expanded sales of Orgovyx and Gemtesa in the US and the benefit of the weaker yen. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as sales of Orgovyx and Gemtesa expanded in the US, also benefiting from the weaker yen. Operating profit decreased due to changes in the product mix associated with the transfer of part of the Asian business, higher selling expenses in the US, increased R&D expenses resulting from the acceleration and advancement of clinical trials, and the absence of the gain on the transfer of equity interests in affiliates recorded in the same period of the previous year. The full-year forecast was revised based on expected upside in US sales, primarily Gemtesa, and a review of the assumed exchange rate.